Abstract: Recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made great strides in enabling better treatment of malignant tumors, especially hematological tumors, as well as increasing the research prospects of potential solid tumor therapies. Consequently, CAR-T therapy is expected to become the selected treatment for patients with relapsed and refractory tumors. Immune checkpoint inhibitors also have certain curative effects in the treatment of cancers, such as liver cancer, refractory Hodgkin's lymphoma, and other malignant tumors, which brings promise to patients with advanced cancer. However, both treatments have different degrees of limitations. Recent clinical trials suggest that combined immune checkpoint inhibitors impair the immunosuppressive effects of the tumor microenvironment, increase the efficacy of CAR-T therapy, and prolong the survival. This article will review the research progress on the combination of CAR-T immunotherapy and immune checkpoint inhibitors in malignancies theray.